Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 21 June

Paulina Peters
June 21, 2022

Morning Bell 20 June

Sophia Mavridis
June 20, 2022

Weekly Wrap 17 June

Sophia Mavridis
June 17, 2022

Morning Bell 16 June

Paulina Peters
June 16, 2022

Morning Bell 15 June

Sophia Mavridis
June 15, 2022

Morning Bell 14 June

Paulina Peters
June 14, 2022

Weekly Wrap 10 June

Sophia Mavridis
June 10, 2022

Morning Bell 9 June

Paulina Peters
June 9, 2022

Morning Bell 8 June

Sophia Mavridis
June 8, 2022

Morning Bell 7 June

Paulina Peters
June 7, 2022

Morning Bell 6 June

Sophia Mavridis
June 6, 2022